{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:31:24Z","timestamp":1770298284532,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2021CFB501"],"award-info":[{"award-number":["2021CFB501"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["ZZYKF202201"],"award-info":[{"award-number":["ZZYKF202201"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Foundation of Hubei Province Key Laboratory","award":["2021CFB501"],"award-info":[{"award-number":["2021CFB501"]}]},{"name":"Open Foundation of Hubei Province Key Laboratory","award":["ZZYKF202201"],"award-info":[{"award-number":["ZZYKF202201"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the Omicron variant in China. A total of 932 patients with confirmed SARS-CoV-2 infection from 18 December 2022 to 1 January 2023 were included in this survey by filling out questionnaires online. The enrolled patients were divided into the primary immunization group and the booster immunization group according to their vaccination status. During the whole course of disease, the most frequent symptoms were fever (90.6%), cough (84.3%), weakness (77.4%), headache and dizziness (76.1%), and myalgia (73.9%). Nearly 90% of the patients had symptoms lasting for less than 10 days, and 39.8% of the patients ended the course of the disease in 4\u20136 days. A total of 58.8% of these patients had a fever with a maximum body temperature of over 38.5 \u00b0C. Moreover, 61.4% of the patients had a fever that lasted less than 2 days. There were no obvious differences in initial symptoms, cardinal symptoms, symptom duration time, maximum body temperature, and fever duration time between the two groups of patients. In addition, no significant difference was found in the positive or negative conversion time of SARS-CoV-2 antigen\/nucleic acid between the two groups of patients. For mild patients with Omicron breakthrough infection, enhanced immunization has no significant impact on the clinical performance and duration of viral infection compared with primary immunization. The reasons behind the different clinical manifestations of patients with mild symptoms after the breakthrough infection of the Omicron strain are still worth further research. Heterologous vaccination may be a better strategy for enhanced immunization, which can help improve the immune protection ability of the population. Further research should be carried out on vaccines against mutant strains and spectral anti-COVID-19 vaccines.<\/jats:p>","DOI":"10.3390\/vaccines11050968","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:29:01Z","timestamp":1683779341000},"page":"968","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy"],"prefix":"10.3390","volume":"11","author":[{"given":"Yingyu","family":"He","sequence":"first","affiliation":[{"name":"Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, China"},{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbing","family":"Liu","sequence":"additional","affiliation":[{"name":"Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, China"},{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6764-3260","authenticated-orcid":false,"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, China"},{"name":"Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 Breakthrough Infections and Reinfections During the Omicron Wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3201\/eid2901.220981","article-title":"SARS-CoV-2 Omicron Ba.5 Infections in Vaccinated Persons, Rural Uganda","volume":"29","author":"Mugisha","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3201\/eid2806.220427","article-title":"SARS-CoV-2 Breakthrough Infections among Us Embassy Staff Members, Uganda, May\u2013June 2021","volume":"28","author":"Harris","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of Mrna-1273 against SARS-CoV-2 Omicron and Delta Variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-022-01874-4","article-title":"Effectiveness of Coronavac in Children 3\u20135 Years of Age During the SARS-CoV-2 Omicron Outbreak in Chile","volume":"28","author":"Jara","year":"2022","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of Bnt162b2 Vaccine against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1038\/s41467-022-35168-7","article-title":"Effectiveness of Chadox1-S COVID-19 Booster Vaccination against the Omicron and Delta Variants in England","volume":"13","author":"Kirsebom","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"Bnt162b2 Protection against the Omicron Variant in Children and Adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Martellucci, C.A., Flacco, M.E., Soldato, G., Di Martino, G., Carota, R., Caponetti, A., and Manzoli, L. (2022). Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and During the Omicron Wave. Vaccines, 10.","DOI":"10.3390\/vaccines10050662"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine Effectiveness of One, Two, and Three Doses of Bnt162b2 and Coronavac against COVID-19 in Hong Kong: A Population-Based Observational Study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth Dose of Bnt162b2 Mrna COVID-19 Vaccine in a Nationwide Setting","volume":"386","author":"Magen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.13273","article-title":"Manifestations of Blood Coagulation and Its Relation to Clinical Outcomes in Severe COVID-19 Patients: Retrospective Analysis","volume":"42","author":"Zhang","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3201\/eid2901.220996","article-title":"Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England","volume":"29","author":"Zaidi","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10787-021-00847-2","article-title":"COVID-19 Vaccines and Decreased Transmission of SARS-CoV-2","volume":"29","author":"Vitiello","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/cimb45020112","article-title":"Vaccine- and Bti-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron Sublineages Ba.1, Ba.2, Ba.4 and Ba.5 Than Pre-Omicron Infection Alone","volume":"45","author":"Servais","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofac138","DOI":"10.1093\/ofid\/ofac138","article-title":"A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease","volume":"9","author":"Higdon","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ghazy, R.M., Ashmawy, R., Hamdy, N.A., Elhadi, Y.A.M., Reyad, O.A., Elmalawany, D., Almaghraby, A., Shaaban, R., and Taha, S.H.N. (2022). Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 10.","DOI":"10.3390\/vaccines10030350"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3201\/eid2802.211789","article-title":"Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants","volume":"28","author":"Kislaya","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nielsen, K.F., Moustsen-Helms, I.R., Schelde, A.B., Gram, M.A., Emborg, H.D., Nielsen, J., Hansen, C.H., Andersen, M.A., Meaidi, M., and Wohlfahrt, J. (2022). Vaccine Effectiveness against SARS-CoV-2 Reinfection During Periods of Alpha, Delta, or Omicron Dominance: A Danish Nationwide Study. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1004037"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons","volume":"385","author":"Kissler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 Doses of Mrna COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"Jama"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1001\/jama.2022.2068","article-title":"Association of Prior Bnt162b2 COVID-19 Vaccination with Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance","volume":"327","author":"Britton","year":"2022","journal-title":"Jama"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"Iga Dominates the Early Neutralizing Antibody Response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wisnewski, A.V., Luna, J.C., and Redlich, C.A. (2021). Human Igg and Iga Responses to COVID-19 Mrna Vaccines. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249499"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2228900","DOI":"10.1001\/jamanetworkopen.2022.28900","article-title":"Analysis of COVID-19 Incidence and Severity among Adults Vaccinated with 2-Dose Mrna COVID-19 or Inactivated SARS-CoV-2 Vaccines with and without Boosters in Singapore","volume":"5","author":"Ng","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","article-title":"Protection by Vaccines and Previous Infection against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"226","author":"Berec","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"940562","DOI":"10.3389\/fimmu.2022.940562","article-title":"Facing the Omicron Variant-How Well Do Vaccines Protect against Mild and Severe COVID-19? Third Interim Analysis of a Living Systematic Review","volume":"13","author":"Piechotta","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-022-01400-4","article-title":"Headache onset after vaccination against SARS-CoV-2: A systematic literature review and meta-analysis","volume":"23","author":"Castaldo","year":"2022","journal-title":"J. Headache Pain"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/968\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:06Z","timestamp":1760124726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["vaccines11050968"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11050968","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}